CD274 and cancer: We found that both AA and CA tumors have a significantly higher expression, when compared to their non-tumor counterparts, of CD274 (FDR for AA 0.03, FDR for CA 0.02) but the expression in CA was 35% higher, suggesting that CA patients may have higher likelihood of qualifying for these immunotherapies than AA patients (Figure 4A).